2. Academic Validation
  3. Characterization and reduction of non-endocrine cells accompanying islet-like endocrine cells differentiated from human iPSC

Characterization and reduction of non-endocrine cells accompanying islet-like endocrine cells differentiated from human iPSC

  • Sci Rep. 2022 Mar 18;12(1):4740. doi: 10.1038/s41598-022-08753-5.
Hideyuki Hiyoshi  # 1 2,  Kensuke Sakuma  # 3 4 5,  Noriko Tsubooka-Yamazoe  # 3 4 5,  Shinya Asano 6,  Taisuke Mochida 3 4,  Junji Yamaura 4 7,  Shuhei Konagaya 8 4 5,  Ryo Fujii 6,  Hirokazu Matsumoto 3 4,  Ryo Ito 3 4 5,  Taro Toyoda 9 10
Affiliations

Affiliations

  • 1 T-CiRA Discovery, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan. hideyuki.hiyoshi@takeda.com.
  • 2 Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Kanagawa, Japan. hideyuki.hiyoshi@takeda.com.
  • 3 T-CiRA Discovery, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
  • 4 Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Kanagawa, Japan.
  • 5 Orizuru Therapeutics, Inc, Fujisawa, Kanagawa, Japan.
  • 6 Axcelead Drug Discovery Partners, Inc, Fujisawa, Kanagawa, Japan.
  • 7 Pharmaceutical Science, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
  • 8 Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • 9 Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. t.toyoda@cira.kyoto-u.ac.jp.
  • 10 Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Kanagawa, Japan. t.toyoda@cira.kyoto-u.ac.jp.
  • # Contributed equally.
PMID: 35304548 DOI: 10.1038/s41598-022-08753-5
Abstract

The differentiation of pancreatic endocrine cells from human pluripotent stem cells has been thoroughly investigated for their application in cell therapy against diabetes. Although non-endocrine cells are inevitable contaminating by-products of the differentiation process, a comprehensive profile of such cells is lacking. Therefore, we characterized non-endocrine cells in iPSC-derived pancreatic islet cells (iPIC) using single-cell transcriptomic analysis. We found that non-endocrine cells consist of (1) heterogeneous proliferating cells, and (2) cells with not only pancreatic traits but also liver or intestinal traits marked by FGB or AGR2. Non-endocrine cells specifically expressed FGFR2, PLK1, and LDHB. We demonstrated that inhibition of pathways involving these genes selectively reduced the number of non-endocrine cells in the differentiation process. These findings provide useful insights into cell purification approaches and contribute to the improvement of the mass production of endocrine cells for stem cell-derived cell therapy for diabetes.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z